Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.50 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4565952 | 1.00 | GABBR2 (0.50) | GABBR2GABBR1PTGS1PTGS2HTT | |
| SCHEMBL1164681 | 0.83 | TNNC1 (0.44) | PTGS1PTGS2HTTCYP2C9ALDH1A1 | |
| SCHEMBL1164679 | 0.83 | TNNC1 (0.44) | PTGS1PTGS2HTTCYP2C9ALDH1A1 | |
| SCHEMBL6071609 | 0.82 | HTT (0.46) | GABBR2GABBR1PTGS1PTGS2HTT | |
| SCHEMBL15299843 | 0.82 | HTT (0.46) | GABBR2GABBR1PTGS1PTGS2HTT | |
| SCHEMBL8072537 | 0.81 | GABBR2 (0.58) | GABBR2GABBR1PTGS1PTGS2HTT | |
| SCHEMBL8072535 | 0.81 | GABBR2 (0.58) | GABBR2GABBR1PTGS1PTGS2HTT | |
| SCHEMBL27447066 | 0.80 | GABBR2 (0.54) | GABBR2GABBR1PTGS1PTGS2HTT | |
| SCHEMBL2189364 | 0.78 | HTT (0.49) | GABBR2GABBR1PTGS1PTGS2HTT | |
| SCHEMBL10296725 | 0.78 | LCK (0.48) | PTGS2ALOX5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005718-A1 | COMPOSITIONS AND METHODS OF TREATING CHRONIC PAIN BY ADMINISTERING PROPOFOL DERIVATIVES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2013-01-03 | — | — | US | disclosed |
| US-7479507-B2 | Anti-inflammatory substituted phenols and elastomeric compositions for oral delivery of drugs | HELLER ADAM | 2009-01-20 | — | — | US | disclosed |
| US-20060258618-A1 | Anti-inflammatory substituted phenols and elastomeric compositions for oral delivery of drugs | HELLER ADAM | 2006-11-16 | — | — | US | disclosed |
| WO-2004064781-A2 | ANTI-INFLAMMATORY SUBSTITUTED PHENOLS AND ELASTOMERIC COMPOSITIONS FOR ORAL DELIVERY OF DRUGS | HELLER ADAM (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258618-A1 | Anti-inflammatory substituted phenols and elastomeric compositions for oral delivery of drugs | PTGES3, PTGES, HPGDS | GABBR2 4258/4885GABBR1 4233/4885PTGS1 6/4885 |
| US-20130005718-A1 | COMPOSITIONS AND METHODS OF TREATING CHRONIC PAIN BY ADMINISTERING PROPOFOL DERIVATIVES | HCN3, HCN1, HCN2 | GABBR2 221/4885GABBR1 218/4885PTGS1 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.